Cargando…
Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors
BACKGROUND: The majority of patients with advanced gastrointestinal stromal tumor (GIST) develop resistance to imatinib, and subsequent treatments have limited efficacy. Ilixadencel (allogeneic inflammatory dendritic cells) is a cell-based immune primer injected intratumorally that previously has be...
Autores principales: | Fröbom, Robin, Berglund, Erik, Berglund, David, Nilsson, Inga-Lena, Åhlén, Jan, von Sivers, Karin, Linder-Stragliotto, Christina, Suenaert, Peter, Karlsson-Parra, Alex, Bränström, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568699/ https://www.ncbi.nlm.nih.gov/pubmed/32535637 http://dx.doi.org/10.1007/s00262-020-02625-5 |
Ejemplares similares
-
Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
por: Karlsson-Parra, Alex, et al.
Publicado: (2018) -
Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma
por: Rizell, Magnus, et al.
Publicado: (2019) -
Wide Surgical Margin Improves the Outcome for Patients with Gastrointestinal Stromal Tumors (GISTs)
por: Åhlén, Jan, et al.
Publicado: (2018) -
The role of neoadjuvant imatinib in gastrointestinal stromal tumor patients: 20 years of experience from a tertial referral center
por: Renberg, Sara, et al.
Publicado: (2022) -
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)